MRSA and MSSA Treatment
First-Line Antibiotic Selection
For MSSA infections, use cefazolin or an anti-staphylococcal penicillin (nafcillin, oxacillin); for MRSA infections, use vancomycin or daptomycin with appropriate dosing. 1
MSSA Treatment Options
Preferred agents:
- Cefazolin 1-2 g IV every 8 hours for hospitalized patients requiring parenteral therapy 2, 3
- Nafcillin or oxacillin 2 g IV every 4-6 hours as alternative IV options 2, 3, 4
- Dicloxacillin 250-500 mg orally every 6 hours for outpatient oral therapy 2, 5, 3
- Cephalexin 500 mg orally every 6 hours as an alternative oral beta-lactam 2, 5
Critical evidence: Studies demonstrate superior outcomes with beta-lactams compared to vancomycin for MSSA bloodstream infections, making de-escalation from empiric MRSA coverage essential once susceptibilities are known. 1, 6
Cefazolin considerations: Recent observational data suggest similar or superior efficacy of cefazolin compared to anti-staphylococcal penicillins, though concern exists about the cefazolin inoculum effect (CzIE) in certain isolates. 1 An Argentine study found higher 30-day mortality (39.5% vs 15.2%) in CzIE-positive isolates, though it remains unclear whether anti-staphylococcal penicillin selection would ameliorate this risk. 1
MRSA Treatment Options
Parenteral therapy (first-line):
- Vancomycin 15-20 mg/kg IV every 8-12 hours (target trough 15-20 mg/L for serious infections) 1, 7, 6
- Daptomycin 4 mg/kg IV once daily for skin/soft tissue infections (higher doses 6-10 mg/kg for bacteremia/endocarditis) 1, 2, 6
- Linezolid 600 mg IV/PO twice daily as an alternative, particularly for pneumonia where it achieves superior lung penetration 1, 7
Oral therapy for skin/soft tissue infections:
- Trimethoprim-sulfamethoxazole 1-2 double-strength tablets (160-320/800-1600 mg) twice daily 8, 5
- Doxycycline 100 mg orally twice daily 8, 5
- Clindamycin 300-450 mg orally every 6-8 hours (use only if local MRSA resistance <10%) 2, 7, 8, 5
Critical pitfall: Doxycycline and trimethoprim-sulfamethoxazole lack reliable activity against beta-hemolytic streptococci and should never be used as monotherapy for typical cellulitis—they must be combined with a beta-lactam when streptococcal coverage is needed. 8, 5
Treatment Duration by Clinical Syndrome
Uncomplicated Skin and Soft Tissue Infections
- 5 days if clinical improvement occurs (resolution of warmth/tenderness, improving erythema, afebrile); extend only if symptoms have not improved 2, 9, 8
- High-quality RCT evidence demonstrates 5-day courses are as effective as 10-day courses for uncomplicated cellulitis 9
Bacteremia
- 4-6 weeks for bacteremia with high-risk features (endocarditis, persistent fever, metastatic foci, implantable devices) 1
- 2 weeks minimum for uncomplicated bacteremia after blood culture clearance 5, 6
- Prolonged bacteremia ≥48 hours is associated with 39% 90-day mortality risk 6
Pneumonia
- 7-21 days depending on extent of infection 7
- Linezolid may be preferred over vancomycin for MRSA pneumonia due to superior lung epithelial lining fluid penetration 7
Complicated Skin/Soft Tissue Infections
Empiric Therapy Considerations
In areas with high MRSA prevalence, should you add empiric beta-lactam to MRSA coverage?
The evidence does not support routine combination therapy. 1 While some have argued for empiric vancomycin/daptomycin plus beta-lactam to optimize upfront therapy for both MSSA and MRSA, retrospective VA data found that early beta-lactam incorporation during MRSA bacteremia treatment may be less beneficial in the modern era with rapid molecular diagnostics. 1 The critical branch point is methicillin susceptibility—once known, tailor therapy accordingly rather than continuing dual coverage. 1
Source Control and Adjunctive Management
Source control is mandatory and includes: 1, 6
- Early removal of infected intravascular or prosthetic devices (failure to remove is associated with higher relapse and mortality) 7, 6
- Drainage of abscesses 8, 6
- Surgical debridement of necrotic tissue 6
- Valve replacement evaluation for endocarditis per AHA guidelines 7
Imaging recommendations:
- Transthoracic echocardiography (TTE) for all patients with S. aureus bacteremia 6
- Transesophageal echocardiography (TEE) preferred in adults due to superior detection of vegetations, intracardiac abscess, and valvular perforation; mandatory for high-risk patients (persistent bacteremia >2-3 days, persistent fever, metastatic foci, implantable cardiac devices) 7, 6
- PET/CT is emerging but mortality benefit questioned due to immortal time bias in observational studies 1
Special Populations
Pediatric Dosing
MSSA:
MRSA:
- Vancomycin 15 mg/kg IV every 6 hours 7, 9
- Clindamycin 10-13 mg/kg/dose IV every 6-8 hours (if stable, no bacteremia, local resistance <10%) 7, 9
- Linezolid 10 mg/kg/dose IV every 8 hours for <12 years; 600 mg twice daily for ≥12 years 7, 9
- Doxycycline contraindicated in children <8 years due to tooth discoloration and bone growth effects 7, 8
Penicillin Allergy
- For non-immediate reactions: cephalosporins remain acceptable (cross-reactivity only 2-4%) 9
- For immediate hypersensitivity: use vancomycin for serious infections or clindamycin for mild infections (if local resistance <10%) 2, 3
Common Pitfalls to Avoid
- Never use vancomycin for MSSA when beta-lactams are available—outcomes are inferior 1, 6
- Do not continue empiric MRSA coverage for typical non-purulent cellulitis without risk factors (penetrating trauma, purulent drainage, injection drug use, MRSA colonization, SIRS) 9, 8
- Do not use cephalosporins or other beta-lactams for MRSA—they have zero activity against methicillin-resistant organisms 8, 10
- Avoid rifampin monotherapy—resistance develops rapidly; use only in combination for specific indications 3, 10
- Do not use daptomycin for pneumonia—it is inactivated by pulmonary surfactant 5
- Reassess within 24-48 hours to verify clinical response, as treatment failure rates of 21% have been reported with some oral regimens 9